These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

290 related items for PubMed ID: 24371842

  • 1. Comparative effectiveness and safety of drug therapy for pulmonary arterial hypertension: a systematic review and meta-analysis.
    Coeytaux RR, Schmit KM, Kraft BD, Kosinski AS, Mingo AM, Vann LM, Gilstrap DL, Hargett CW, Heidenfelder B, Dolor RJ, McCrory DC.
    Chest; 2014 May; 145(5):1055-1063. PubMed ID: 24371842
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial.
    Tapson VF, Torres F, Kermeen F, Keogh AM, Allen RP, Frantz RP, Badesch DB, Frost AE, Shapiro SM, Laliberte K, Sigman J, Arneson C, Galiè N.
    Chest; 2012 Dec; 142(6):1383-1390. PubMed ID: 22628490
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. What is the position of pulmonary arterial hypertension-specific drug therapy in patients with Eisenmenger syndrome: A systematic review and meta-analysis.
    Li Q, Kuang HY, Wu YH, Lu TW, Yi QJ.
    Medicine (Baltimore); 2019 May; 98(20):e15632. PubMed ID: 31096477
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Dual therapy in IPAH and SSc-PAH. A qualitative systematic review.
    Johnson SR, Brode SK, Mielniczuk LM, Granton JT.
    Respir Med; 2012 May; 106(5):730-9. PubMed ID: 22366298
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Combination therapy in pulmonary arterial hypertension: a meta-analysis.
    Bai Y, Sun L, Hu S, Wei Y.
    Cardiology; 2011 May; 120(3):157-65. PubMed ID: 22212696
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Dual phosphodiesterase type 5 inhibitor therapy for refractory pulmonary arterial hypertension: a pilot study.
    Kimura M, Tamura Y, Takei M, Yamamoto T, Ono T, Fujita J, Kataoka M, Kuwana M, Satoh T, Fukuda K.
    BMC Pulm Med; 2015 May 14; 15():62. PubMed ID: 25971443
    [Abstract] [Full Text] [Related]

  • 19. Incremental burden of disease in patients diagnosed with pulmonary arterial hypertension receiving monotherapy and combination vasodilator therapy.
    Small M, Piercy J, Pike J, Cerulli A.
    Adv Ther; 2014 Feb 14; 31(2):168-79. PubMed ID: 24449285
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.